Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
$3.22
+3.5%
$3.22
$1.58
$6.94
$648.31M2.021.24 million shs3.62 million shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.02
$0.02
$0.25
$3.56
$708K2.34455,220 shsN/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
0.00%0.00%0.00%0.00%0.00%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%0.00%0.00%-14.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
$3.22
+3.5%
$3.22
$1.58
$6.94
$648.31M2.021.24 million shs3.62 million shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.02
$0.02
$0.25
$3.56
$708K2.34455,220 shsN/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
0.00%0.00%0.00%0.00%0.00%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%0.00%0.00%-14.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
0.00
N/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
$112.92M5.74N/AN/A$0.26 per share12.38
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$18.16M0.04N/AN/A$1.94 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
-$165.34M-$0.42N/AN/AN/A-28.38%58.50%8.12%N/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
N/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
2.25
0.45
0.44
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/A
3.50
3.50

Institutional Ownership

CompanyInstitutional Ownership
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
25.92%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
38.51%

Insider Ownership

CompanyInsider Ownership
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
27.00%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Contango Oil & Gas stock logo
MCF
Contango Oil & Gas
205201.34 million146.98 millionNot Optionable
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
1,62029.49 million24.77 millionNot Optionable

Recent News About These Companies

Arsenal Yards attracts another life sciences tenant
SQZB SQZ Biotechnologies Company - Seeking Alpha
Serica Energy shares drop as Triton suspended until mid-March
Serica Energy says 2025 outlook is ‘promising'
SQZ Biotechnologies Co Ordinary Shares
SQZ Biotechnologies Company (SQZB)
Sqz Bio (SQZB) Earnings Dates & Reports
VC funding update: who raised money in March?
SQZB SQZ Biotechnologies Company

Media Sentiment Over Time

Contango Oil & Gas stock logo

Contango Oil & Gas NYSEAMERICAN:MCF

$3.22 +0.11 (+3.54%)
As of 12/7/2021

Contango Oil & Gas Co. is an oil and natural gas company. The firm engages in the exploration, development, production and acquisition of crude oil and natural gas properties. Its operation focuses in Permian Basin, South Texas, Southeast Texas East Texas, Wyoming, and Gulf of Mexico. The company was founded by Kenneth R. Peak on August 7, 1986 and is headquartered in Fort Worth, TX.

SQZ Biotechnologies stock logo

SQZ Biotechnologies NYSE:SQZ

$0.02 0.00 (0.00%)
As of 05/5/2026

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.